182 results about "Virus type" patented technology

Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.

The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non HLA-restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV infected cells when expressed by a CTL.

The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.

The invention discloses a cryopreservation method of umbilical cord tissue blocks, and relates to a cryopreservation method of umbilical cords. The invention aims at solving the problems that the preservation time of umbilical cord tissues is short, and the cell death of the umbilical cord tissues is easily caused at present. The method comprises the following steps: 1, carrying out treatment of the tissue blocks, namely in a sterile operating platform, carrying out disinfection treatment on an umbilical cord, cleaning the umbilical cord normal saline, shearing the umbilical cord into segments, peeling off a wharton jelly, placing the wharton jelly in a clean centrifuging tube and cutting the wharton jelly into pieces; and 2, adding DMEM in the tissue blocks, resuspending the tissue blocks, then adding a pre-cooling cryopreservation liquid, sub-packaging the tissue blocks in cryopreservation tubes, cooling by use of a program-controlled cooler, and transferring the tissue blocks in liquid nitrogen for long-time storage after bacterial detection, microbiological detection and virus detection are all negative, so as to finish the cryopreservation of the umbilical cord tissue blocks. The directly-inoculated adherent survival rate of the cryopreserved and unfrozen tissue blocks in culture bottles is more than 98%, the cell growth is good, and moreover, an osteogenic differentiation experiment carried out on the cultured cells of the cryopreserved tissue blocks indicates that the differentiation function is high. The method is used for storing the umbilical cord tissues.

The invention provides a preparation method of a cytokine-induced killing cell for inducing antibody-dependent cellular cytotoxicity. The preparation method comprises constructing an interferon gamma signal peptide-tumor cell combined peptide, bonding 2th and 3th constant region gene segments of a crystallizable fragment domain heavy chain to the combined peptide, recombining the combined chain to a viral vector, transfecting a human cytokine-induced killing cell and carrying out high expression of a 2th and 3th constant region fusion protein of a novel polypeptide-crystallizable fragment domain heavy chain. The preparation method can cause antibody-dependent cellular cytotoxicity, improve a cytokine-induced killing cell proliferation multiple to 1000 times or more, a CD3+ / CD56+ expression rate to 40% or more and a CD16+ expression rate to 30% or more. In-vivo and in-vitro tests prove that the cytokine-induced killing cell has strong tumor killing toxicity. The invention also provides a kit for autologous cytokine-induced killing cell proliferation culture and has a high-efficiency anti-tumor function.

The invention relates to a lentivirus vector expression system of luciferase and an application thereof. Particularly speaking, in the invention a luciferase lentivirus expression system with FG12-Luc2 as core plasmid is successfully constructed, and a PVTT-1 cell line from tumor thrombus tissue of liver cancer patients is established by the system. Through the lentivirus expression system, liver cancer tissue is successfully marked; and by experimental methods such as subcutaneous transplantation and orthotopic liver cancer transplantation, a mouse orthotopic transplantation liver cancer metastasis model is established which is suitable for serial passage, is applicable to in-vivo imaging, and can realize real-time monitoring of the growth and metastasis conditions of tumors in the body.

The invention comprises a novel virus that can kill mammalian cancer cells efficiently. The virus produces a novel protein that converts two non-toxic prodrugs into potent chemotherapeutic agents. These chemotherapeutic agents are produced locally and help the virus kill the cancer cells as well as sensitize them to radiation. In preclinical studies, the virus has proven effective at killing a variety of mammalian cancer cells either alone or when combined with prodrug therapy and / or radiation therapy. The invention may provide a safe and effective treatment for human cancer.

The invention provides a TRAIL secretion mesenchyma stem cell and a purpose thereof for encephaloma treatment, and relates to the field of gene recombination and stem cell application. Particularly, the invention provides a building body for expressing a secretion type TRAIL protein soluble fragment and a slow virus expression vector containing the building body. The invention also provides the mesenchyma stem cell integrating the building body on the genome; the TRAIL protein fragment can be expressed and secreted. The invention also provides application of the building body or the vector or the mesenchyma stem cell to encephaloma treatment.

The invention provides a preparation method of a placenta source matrix mesenchymal stem cell. The preparation method comprises the following steps: (1) separating the placenta source matrix mesenchymal stem cell; (2) cultivating the placenta source matrix mesenchymal stem cell, wherein a trypLE<TM> enzyme solution is utilized to process a placenta tissue in two steps in the step (1), and a serum-free medium is utilized in the step (2). By adopting the method provided by the invention, the placenta source matrix mesenchymal stem cell is a complete matrix source by short tandem repeat sequence (STR) atlas analysis, and is qualified by chromosome karyotype examination, pathogenic microorganism examination of bacteria, funguses and viruses, cell purity identification and cell biology function identification. Therefore, the placenta source matrix mesenchymal stem cell obtained by the method provided by the invention does not contain foreign protein, can meet the requirements of clinical use, is especially suitable for use by mothers, and also provides a technical support for building an excellent placenta source matrix mesenchymal stem cell bank.

The present invention is directed to the administration of FusOn-H2, an HSV derived oncolytic virus, to treat tumor cells that are resistant to the lytic effect of the virus. Administration of FusOn-H2 induces the patient's innate immune responses to tumor cells via neutrophils, which are able to destroy tumors efficiently when they migrate to the tumor mass. With the induced innate antitumor immunity, FusOn-H2 is effective at eradicating tumors even when it is used at very low doses.